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Background: Beta1 (B1) selective blockers have been widely used for the treatment of 
  neurocardiogenic syncope though clinical trials have shown conflicting degrees of efficacy.
Objective: To study the clinical efficacy of B1 selective blockers compared to placebo in the 
treatment of neurocardiogenic syncope.
Methods: Four placebo controlled randomized studies were identified after search of existing 
English language literature. Review Manager (RevMan version 5, Oxford, England) was used 
for statistical calculations. Both random and fixed effects models were used for analysis.
Results: There was no demonstrable efficacy of B1 blockers compared to placebo even after 
a pre-specified sensitivity analysis. There was a trend towards more adverse events in the beta 
blocker group compared to placebo (OR = 2.03 CI = 0.83–3.95, p = 0.12).
Conclusion: There is no clinical evidence for justifying the use of B1 selective blockers in the 
treatment of adult neurocardiogenic syncope. These agents may in fact lead to a higher rate of 
adverse events compared to placebo.
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Neurocardiogenic syncope (or neurally mediated syncope) is a disorder of unknown 
pathogenesis which leads to transient loss of consciousness due to a failure of the 
body’s reflex mechanisms to maintain adequate cerebral perfusion.1 It accounts for 
about 21.2% of all causes of syncope with an incidence of 6.2 per 1000 person years 
for first reported syncope.2 The exact pathogenesis of this disorder remains uncertain.3 
There is no proven therapy though many classes of medications are prescribed. Both 
non selective and selective beta blockers have been used in clinical practice. There 
is an elevation of plasma catecholamines before both spontaneous and tilt-induced 
syncope, making beta adrenergic blockade an attractive option. They have also been 
postulated to decrease mechanoreceptor activation due to their negative inotropic 
effects thus preventing decreased venous return.4 Initial non randomized studies and 
one randomized controlled study added to the enthusiasm. However, recent random-
ized controlled studies have failed to prove the efficacy of selective b1 (B1) blockade 
in this disorder. We performed a meta-analysis to determine the clinical efficacy of 
oral B1 selective blockade in the treatment of neurocardiogenic syncope and to study 
the side effect profile compared to placebo.
Methods
Study identification
We searched the PubMed, CINAHL, Web of Science, and Cochrane databases from 
inception to 2009 using MeSH terms “vasovagal syncope” “drug therapy”   “adrenergic Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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beta antagonists” and individually using the key words 
  “vasovagal syncope” “neurocardiogenic   syncope”   “treatment” 
“metoprolol” “ atenolol” “nebivolol”   “bisoprolol” “aceb-
utalol” “betaxolol” and “beta blocker”. The “related article” 
feature was used to identify more related studies. References 
of individual articles were manually searched. HSRProj and 
National Research Register databases were used to identify 
any “grey” literature.
study selection
The aim was to include randomized controlled studies that 
studied the clinical efficacy of oral B1 blockade compared 
to placebo in patients above 18 years of age with a diagnosis 
of neurocardiogenic syncope. Since there is no therapy with 
proven efficacy in this disorder, we did not include studies 
that compared B1 blockers with another drug. Due to the 
absence of a “gold standard” for the diagnosis of this condi-
tion, a diagnosis of neurocardiogenic syncope as determined 
by the study investigators was considered acceptable as case 
definition. A careful cardiovascular and neurological inves-
tigation was considered essential inclusion criteria before 
such a diagnosis could be made. Clinical recurrence was 
defined as occurrence of syncope while on therapy or a lack 
of perceived benefit. Studies which reported only the effect 
on tilt-induced syncope were excluded. A total of hundred and 
sixteen studies were identified. Seven randomized   controlled 
trials were identified through a process described in Figure 1. 
Four of these studies compared B1 blockade with placebo4–7 
and one each with clonidine,8 propranolol,9 and no therapy.10 
Only studies that included a placebo arm were included in 
the analysis. In the study by Brignole et al only the patients 
who underwent randomization were included in the analysis.4 
Perceived lack of improvement was the outcome studied 
by Mahanonda et al6 while other studies reported rates of 
recurrence. Other than Madrid et al,5 studies only included 
patients who had a positive head up tilt table test as part of 
the case definition.
Data extraction
Two reviewers used a standard form to extract data inde-
pendently. Disagreements were resolved after discussion. 
Efficacy data was extracted from the intention to treat analysis 
of all studies. The number of patients suffering adverse events 
was also identified.
Quality of studies
Each study was assigned a Jadad score by the two authors 
independently. A score of 3 or more was felt to be criteria for 
inclusion. After discussion, consensus was reached and the 
studies included were felt to be of satisfactory quality.
statistical analysis
Review Manager (RevMan version 5, Oxford, England) was 
used for statistical calculations. Results of individual studies 
and overall result was expressed as an odds ratio (OR) with 
95% confidence intervals (CI). A 2-sided p value less than 
0.05 was considered statistically significant. I2 test was used 
as a measure of heterogeneity and the random effects model 
was used for analysis when significant heterogeneity (defined 
as I2 . 50%) was present. A post-hoc sensitivity analysis 
was planned in case of significant heterogeneity including 
studies with similar outcome measures and mean follow up 
duration.
Description of studies included
Table 1 describes the randomized controlled trials included in 
the meta analysis. Brignole and colleagues in 1992 random-
ized patients to drug therapy with various drugs including 
atenolol, dihydroergotamine, cafedrine, domperidone, and 
elastic compression stockings with or without drugs to place-
bo.4 Only the patients treated with atenolol alone (n = 7) were 
included and compared to the placebo group. The inclusion 
criteria required subjects to have two consecutive positive 
upright tilt table tests to be considered for the study. The study 
did not report a significant difference between any of the drug 
therapies compared to placebo. Atenolol was also compared 
to placebo in a randomized controlled study by Mahanonda 
et al.5 Patients with a history suggestive of vasovagal syncope 
were ruled out for structural heart disease and included in the 
study after a positive isoproterenol tilt table test. In addition 
to a statistically significant increase in patients reporting 
feeling better compared to placebo (p = 0.02), patients in the 
atenolol group had a drop in the number of episodes from 
6 ± 9.4/week to 0.6 ± 1.6 per week (p = 0.025). However, 
in the study by Madrid and colleagues, atenolol failed to 
decrease the recurrence of syncope compared to placebo.6 
The median number of syncopal episodes during follow up 
was 2 in atenolol group and 0 in placebo group (p = 0.215).
The largest trial and the only multicenter study to date was 
performed by Sheldon et al who randomized patients with a 
history of syncope and a positive tilt table test to metoprolol 
versus placebo.7 Metoprolol was no more efficacious than 
placebo in preventing recurrent syncope both in the intention 
to treat and on-treatment analysis. Sample size calculation 
with a study power of 80% was performed and reported in 
the latter three studies.5–7Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Results of meta-analysis
There was no demonstrable efficacy of B1 blockers compared 
to placebo as demonstrated in Figure 2. There was significant 
heterogeneity (I2 = 64%) among the studies. When the analysis 
was repeated using a fixed effects model, there was still no 
statistically significant difference (OR = 0.92, CI = 0.59–1.43, 
p = 0.7). Using a pre-specified sensitivity analysis, the study 
by Mahanonda et al was excluded due to the shorter follow-up 
period (1 month), which yielded a I2 of 0% with an OR = 1.18 
(CI = 0.73–1.92, p = 0.5). Further sensitivity analyses not 
specified before the study were completed in view of these 
results showing no efficacy. Analysis performed by excluding 
the study with the lowest number of subjects (Brignole et al4 
which also did not report a sample size calculation) and by 
including only studies with atenolol (Brignole et al,   Mahanonda 
et al and Madrid et al) did not reveal any significant benefit 
from using B1 blockers compared to placebo (OR = 0.75, 
CI = 0.23–2.40, p = 0.63 and OR = 0.69, CI = 0.13–3.59, 
p = 0.66 respectively). Significant heterogeneity persisted in 
both of these analyses (I2 = 74 and 70% respectively). There 
were more adverse events in the beta blocker group (15 vs 8, 
OR = 2.03, CI = 0.83–3.95, p = 0.12). Funnel plot analysis 
was not performed due to the small number of studies since 
such an analysis may be misleading.11
Discussion
Neurocardiogenic syncope is a common disorder that results 
in transient loss of consciousness. The pathophysiology of 
this disorder is incompletely understood. Some have even 
questioned the existence of this disorder as a separate entity. 
In patients who are predisposed to this condition, reduced 
venous return from the lower extremities causes a decrease 
in the preload; the resultant decrease in cardiac output and 
blood pressure causes activation of the baroreceptor reflex.3 
This causes an increase in ventricular contractility which is 
sensed by mechanoreceptors in the heart which project to the 
medullary dorsal vagal nucleus. A withdrawal of peripheral 
sympathetic tone and an increase in the vagal tone ensues 
resulting in vasodilation and bradycardia leading to clinical 
symptoms. This mechanism however discounts the importance 
of central mechanisms, which may contribute to syncope. 
There is some evidence of the importance of serotoninergic 
pathways which is supported by the evidence of the response 
of some patients to serotonin reuptake inhibitors.12 Several 
drugs including non selective and selective beta blockers, 
clonidine, midodrine, fludrocortisone, and SSRIs have been 
studied in the treatment of this disorder.5 Beta blockers (both 
selective and non selective) are commonly used medications 
in the treatment of patients diagnosed with neurocardiogenic 
116 studies identified after initial search
Articles reviewed in detail 30
Non-selective beta blockade 5
Studies eliminated 23
Review 1
Meta-analysis 1
Pacing arm 2
Retrospective studies 2
Clinical outcomes not studied/reported 5
Non-randomized studies 7
Prospective studies not related to beta blocker therapy
pathophysiology 9, clinical course 6, diagnostic testing 4
prognosis 3, pacing 3, other drugs 3,
Studies eliminated after review of abstract 89
Retrospective studies 12
Case reports and series 10
Letters to the editor 6
Reviews 23, editorial 3
Pediatric population 7
Reference list search 3 articles added
Vs placebo(4), clonidine(1), propranolol(1), no
therapy(1)
Randomized controlled trials 7
Figure 1 Flowchart describing the methods of study selection.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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) syncope. We chose to study the rates of clinical recurrence of 
syncope while on B1 blocker therapy because of the practical 
clinical importance rather than study the response to tilt. We 
found no statistically significant improvement in clinical rates 
of recurrence of syncope with B1 blockers. There was actually 
an increased risk of adverse events though statistically not 
significant. The lack of clinical efficacy of B1 blockers may 
relate partly to the lack of understanding of the pathophysiol-
ogy of neurocardiogenic syncope. The initial non randomized 
studies may simply have reflected the placebo nature of the 
administration of these medications. Adrenoreceptor stimu-
lation in the heart may not play a major role in provoking 
syncope and thus selective B1 blockers may be ineffective. 
Non selective beta blockers such as propranolol may in fact 
be more effective by virtue of inhibition of the vasodilatory 
effect of activation of B2 receptor.13 In view of this difference; 
we did not include non selective blockers in this analysis 
as it would constitute an inhomogeneous treatment group. 
However, a randomized, placebo controlled study by Flevari 
et al failed to show the efficacy of non selective beta blockers 
(propranolol and nadolol) compared to placebo.14
Haghjoo et al reported similar efficacy of propranolol 
and metoprolol but the study lacked a placebo arm and the 
efficacy of these drugs may simply relate to a placebo effect.9 
There may be a small subgroup of patients who may benefit 
from B1 blocker therapy but this has not been adequately 
represented in these trials. Sheldon et al studied two such 
subgroups in a prespecified analysis based on age (less than or 
greater than 42 years) and need for isoproterenol to provoke 
a positive tilt study and neither group appeared to benefit 
from B1 blocker therapy.
Limitations
We included only randomized controlled trials that included a 
placebo arm. There is evidence for a strong placebo effect in the 
treatment of neurocardiogenic syncope and the importance of 
including a placebo arm while studying this disorder has been 
described.15 This prompted the exclusion of one randomized 
study (Ventura et al) which included a no treatment arm.10 This 
meta-analysis thus included only a small number of studies 
(n = 4). We also did not consider studies comparing B1 blockers 
to other medications (for example, non-selective b-blockers) 
because the comparative drug may in fact be no better than 
placebo. We feel that these strict inclusion criteria actually 
enhance the value of this analysis. There was significant het-
erogeneity among the studies, which resolved with the deletion 
of one study in the pre specified sensitivity analysis. Hetero-
geneity persisted in the other sensitivity analysis, which failed Clinical Pharmacology: Advances and Applications
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to prove clinical efficacy. Atenolol is a hydrophilic B1 blocker 
while metoprolol by virtue of its lipophilic nature may cross the 
blood–brain barrier more readily. The treatment arm thus does 
not include medications with similar mechanisms of actions. 
However, studies with atenolol alone did not reach significance 
in the sensitivity analysis. Another limitation common to all 
studies of neurocardiogenic syncope is the variable course of 
the disease with some patients experiencing long periods of 
remission between episodes of syncope.16 Some patients may 
even experience spontaneous remission. This complicates the 
assessment of the clinical efficacy of a drug in the treatment 
of this condition.
Conclusion
We performed this meta analysis to study the clinical efficacy 
of B1 adrenergic blockade in preventing clinical recurrence of 
syncope and to determine the rate of adverse events compared 
to placebo. Our results indicate a lack of clinical efficacy of 
these drugs and in fact a statistically non significant increase 
in adverse events. More randomized controlled studies are 
required to identify other effective therapies for this poorly 
understood disorder and a placebo arm should be a part of 
all such studies.
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